Drugs /

zanidatamab

Back to Drugs List

Overview

NCI Definition [1]:
An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This also induces a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. Antibody-dependent cellular phagocytosis (ADCP) is also induced and further stimulates the immune system to kill HER2-overexpressing tumor cells. The HER2 receptor internalization also further inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

Clinical Trials

View Clinical Trials for zanidatamab

Zanidatamab has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating zanidatamab, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for zanidatamab clinical trials.

Adenocarcinoma of the gastroesophageal junction, breast carcinoma, and gastric adenocarcinoma are the most common diseases being investigated in zanidatamab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Zanidatamab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating zanidatamab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
her2 x her2 bispecific antibody zw25, zw-25, anti-her2/her2 bispecific antibody zw25, zw25
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C130010

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.